Prostate cancer
Oncology· 7 reviewed drugs· 11048 cited findings behind them
What the regulatory reviews cover
This library contains regulatory review documents for several drugs indicated for prostate cancer. Zytiga is indicated for metastatic castration-resistant prostate cancer and newly diagnosed high-risk metastatic hormone-sensitive prostate cancer. Its review documents report a Median OS (abiraterone acetate) of 35.3 months compared to 30.1 months for placebo. Nubeqa, indicated for metastatic hormone-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer, showed an Estimated median MFS (darolutamide) of 40.4 compared to 18.4 for placebo. Erleada, for non-metastatic, castration-resistant prostate cancer, demonstrated a Median Metastasis Free Survival (MFS) in the apalutamide arm of 40.51 months versus 16.20 months in the placebo arm. Xtandi, for metastatic castration-resistant prostate cancer and metastatic castration-sensitive cancer, reported a median rPFS (months) for placebo of 19.0. It is important to note that these drugs were studied in different trials, and therefore, the reported figures are not directly comparable head-to-head.
The drugs — one cited result each
| Taxotere Sanofi | 3154 cited findings on the drug page → |
| Zytiga Johnson & Johnson | Median OS (abiraterone acetate): 35.3 months Zytiga FDA Review, p.42 |
| Nubeqa Bayer Aktiengesellschaft | Estimated median MFS (darolutamide): 40.4 Nubeqa FDA Review (NDA212099, ORI, p.147 |
| AKEEGA Johnson & Johnson | 1327 cited findings on the drug page → |
| Erleada Johnson & Johnson | Median Metastasis Free Survival (MFS) in apalutamide arm: 40.51 months Erleada FDA Review (NDA210951, ORIG 1, 2, p.18 |
| Jevtana Sanofi | 772 cited findings on the drug page → |
| Xtandi Astellas Pharma Inc. | median rPFS (months) for placebo: 19.0 Xtandi EMA EPAR variation assessment, p.96 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Oncology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.